As the nature of RAS protein, target of RAS remains challenging, some inhibitors have been invented to target RAF and MEK1, however, there is poorly clinical benefit in monotherapy for the treatment of advanced CRC patients mostly for the feedback reactivation of MEK1/ERK pathway [5]. The gene discussed is MAP2K1; the disease is colorectal carcinoma.